Acute Kidney Injury | TreatmentTrends | US | 2015
This report examines the management of acute kidney injury (AKI) patients from the perspective of nephrologists and critical care physicians in the US. Emphasis is on self-reported patient load, patient demographics, changes and challenges in AKI management, diagnosis and use of AKI staging criteria, treatment of AKI (such as fluid management, intermittent hemodialysis, and bicarbonate), and impact of contrast-induced nephropathy. In addition, the report covers the future of AKI extensively and provides perceptions of four emerging products in development for the prevention/treatment of AKI. The report is the third wave of this series.
Related Market Assessment Reports
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
